Blood Screening Market a Comprehensive Study by Top Players: Grifols, Roche, Abbott, Biomérieux, Bio-Rad Laboratories

A blood screening is the process of laboratory testing for extracting blood prior to blood transfusion. The test is performed to ensure that recipients receive safe blood products. There are various blood screening procedures for donated blood to ensure that blood units are safe. Blood samples collected during donation undergo laboratory screening for Transfusion-Transmissible Infections (TTIs). In screening technique, blood sample is tested for evidence of certain infectious disease pathogens such as hepatitis B and C viruses and human immunodeficiency virus (HIV).

Increasing demand for NAT over ELISA (enzyme-linked immunosorbent assay) test due to high sensitivity and specificity for viral nucleic acid is boosting growth of the blood screening market. For instance, in 2018, Grifols received approval from the U.S. Food & Drug Administration (FDA) for two blood screening assays- Procleix Ultrio Elite and Procleix WNV. Both assays run on the fully automated NAT blood screening platform: Procleix Panther system. The Procleix Panther system with these assays helps blood centers to efficiently screen for infectious diseases and eliminates the need of batch processing.

Click here for free sample + related graphs of the report @: https://www.coherentmarketinsights.com/insight/request-sample/2409

Increase in initiatives by the government to create awareness among the people regarding safety of the donated blood is expected to drive growth of the market. For instance, in 2014, World Health Organization (WHO) recommended to establish a national blood system with well-organized and coordinated blood transfusion services, effective evidence-based and ethical national blood policies, and legislation and regulation that can provide sufficient and timely supplies of safe blood and blood products to meet the transfusion needs of all patients.

Geographically, North America is expected to dominate the blood screening market, owing to acquisitions by major players in the region. For Instance, in July 2017, Grifols acquired the NAT (Nucleic Acid Testing) donor screening unit from the U.S. Company Hologic for a purchase price of US$ 1,850 Million. This agreement bound to research, development, and manufacture of assays and instruments activities by using NAT technology that allows detection of infectious agents present in blood and plasma donations, contributing to greater transfusion safety.

Blood Screening Market- Competitive Landscape

Key Player operating in the blood screening market include Grifols, F. Hoffmann-La Roche, Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthineers (A Subsidiary of Siemens AG), Ortho Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Beckman Coulter (A Subsidiary of Danaher Corporation) and Becton, Dickinson and Company.

Key Development

In July 2019, Abbott Laboratories, received the U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity s System. Alinity s System is designed to screen blood and plasma more efficiently in less space and also generate the test results consuming less tume and minimum human error.
In 2018, LifeCell International Pvt. Ltd launched RightStart, an integrated DNA-based screening for the diagnosis of more than 50 medical conditions among newborn patients.

In 2017, Clinical Genomics Pty Ltd, launched circulating tumor DNA (ctDNA) blood-based test for the detection of colorectal cancer.

In 2016, Hologic, Inc and Grifols, S.A being in a partnership agreement, received the US Food and Drug Administration (FDA) approval for its Procleix Zika virus blood screening assay.

In 2016, F. Hoffmann-La Roche Ltd, received US Food and Drug Administration (FDA) approval for its cobas MPX test applicable with analyzers like cobas 6800 and 8800 Systems for the detection of HIV-1, HIV-2, HBV and HCV.

To get this report buy full copy @: https://www.coherentmarketinsights.com/insight/buy-now/2409

Blood Screening Market- Taxonomy

By Technology:

Nucleic acid amplification technology (NAT)
ELISA
Immunoassays (IAs)
Next-Generation Sequencing (NGS)
Western Blotting
By Product Type

Reagents & Kits
Instruments
By End User:

Hospital
Blood Banks
Diagnostics Laboratory
By Region

North America
Europe
Asia Pacific
Latin America
Middle East
Africa

For More Information Read Table of Content @: https://www.coherentmarketinsights.com/ongoing-insight/toc/2409

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide.

This release was published on openPR.